Nurtec™ ODT (rimegepant) 75 mg Orally Disintegrating Tablets for Healthcare Professionals

A single quick-dissolving dose can1-3:

Eliminate migraine pain and
get your patients back to function

In a multi-center, double-blind, randomized, placebo-controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), including patients with stable cardiovascular (CV) disease or CV risk factors1,3:

  • Co-primary endpoints at 2 h for Nurtec ODT vs placebo were pain freedom (21% vs 11%, p<0.001) and freedom from most bothersome symptom (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%, p=0.001).1
  • Select secondary endpoints at 60 minutes for Nurtec ODT vs placebo were pain relief (37% vs 31%, p<0.05) and freedom from functional disability (22% vs 16%, p=0.0025); from 2-48 h for Nurtec ODT vs placebo were pain freedom (14% vs 5%, p<0.001), freedom from functional disability (26% vs 15%, p<0.0001), and pain relief (42% vs 25%, p<0.0001).1-3

*Nurtec ODT can be taken as needed up to once daily.1

Per 8-tablet prescription. See Terms & Conditions

See full study design

Discover what one dose can do for your patients

See efficacy

Actor Portrayal

Get your patients back to what matters most1

Help your patients save on Nurtec ODT

view savings program

References: 1. Nurtec ODT [prescribing information]. New Haven, CT: Biohaven Pharmaceuticals, Inc. 2. Croop R et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. 3. Data on File 001. Biohaven Pharmaceuticals, Inc.

Important Safety Information

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.

Indication

Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.

Please click here for full Prescribing Information.